Suppr超能文献

家族性和多腺体原发性甲状旁腺功能亢进症中的 GCM2 变异。

GCM2 Variants in Familial and Multiglandular Primary Hyperparathyroidism.

机构信息

Center for Molecular Oncology, University of Connecticut School of Medicine, Farmington, CT, USA.

Yale Endocrine Neoplasia Laboratory, Department of Surgery, Yale School of Medicine, New Haven, CT, USA.

出版信息

J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2021-e2026. doi: 10.1210/clinem/dgab929.

Abstract

CONTEXT

Multiglandular and familial parathyroid disease constitute important fractions of primary hyperparathyroidism (PHPT). Germline missense variants of GCM2, a regulator of parathyroid development, were observed in familial isolated hyperparathyroidism and sporadic PHPT. However, as these previously reported GCM2 variants occur at relatively high frequencies in the population, understanding their potential clinical utility will require both additional penetrance data and functional evidence relevant to tumorigenicity.

OBJECTIVE

Determine the frequency of GCM2 variants of interest among patients with sporadic multigland or familial parathyroid disease and assess their penetrance.

DESIGN AND PATIENTS

DNA-encoding PHPT-associated GCM2 germline variants were polymerase chain reaction-amplified and sequenced from 107 patients with either sporadic multigland or suspected/confirmed familial parathyroid tumors.

RESULTS

GCM2 variants were observed in 9 of 107 cases (8.4%): Y282D in 4 patients (6.3%) with sporadic multigland disease; Y394S in 2 patients (11.1%) with familial PHPT and 3 (4.8%) with sporadic multigland disease. Compared with the general population, Y282D was enriched 5.9-fold in multigland disease, but its penetrance was very low (0.02%). Y394S was enriched 79-fold in sporadic multigland disease and 93-fold in familial PHPT, but its penetrance was low (1.33% and 1.04%, respectively).

CONCLUSIONS

Observed in vitro-activating GCM2 variant alleles are significantly overrepresented in PHPT patients with multiglandular or familial disease compared to the general population, yet penetrance values are very low; that is, most individuals with these variants in the population have a very low risk of developing PHPT. The potential clinical utility of detecting these GCM2 variants requires further investigation, including assessing their possible role as pathogenic/low-penetrance alleles.

摘要

背景

多腺体和家族性甲状旁腺疾病是原发性甲状旁腺功能亢进症(PHPT)的重要组成部分。在家族性孤立性甲状旁腺功能亢进症和散发性 PHPT 中观察到甲状旁腺发育调节剂 GCM2 的种系错义变异。然而,由于这些先前报道的 GCM2 变异在人群中发生的频率相对较高,因此了解其潜在的临床实用性将需要额外的外显率数据和与致瘤性相关的功能证据。

目的

确定散发性多腺体或家族性甲状旁腺疾病患者中感兴趣的 GCM2 变异的频率,并评估其外显率。

设计和患者

从 107 例散发性多腺体或疑似/确诊家族性甲状旁腺瘤患者中,聚合酶链反应扩增并测序与 PHPT 相关的 GCM2 种系变异的 DNA 编码。

结果

在 107 例病例中的 9 例(8.4%)中观察到 GCM2 变异:4 例(6.3%)散发性多腺体疾病患者中存在 Y282D;2 例(11.1%)家族性 PHPT 患者和 3 例(4.8%)散发性多腺体疾病患者中存在 Y394S。与一般人群相比,Y282D 在多腺体疾病中富集了 5.9 倍,但外显率很低(0.02%)。Y394S 在散发性多腺体疾病和家族性 PHPT 中分别富集了 79 倍和 93 倍,但外显率较低(分别为 1.33%和 1.04%)。

结论

与一般人群相比,在多腺体或家族性疾病的 PHPT 患者中观察到体外激活 GCM2 变异等位基因显著过表达,但外显率非常低;也就是说,人群中具有这些变异的大多数个体发生 PHPT 的风险非常低。检测这些 GCM2 变异的潜在临床实用性需要进一步研究,包括评估它们作为致病性/低外显率等位基因的可能作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验